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Background: Activation of vitamin D is severely impaired in patients with advanced stages of chronic kidney
disease, particularly those on hemodialysis. Observational studies have shown that the use of vitamin D receptor
activators (VDRAs) is associated with lower risk of death from all-cause and cardiovascular disease (CVD) in dialysis
populations regardless of serum parathyroid hormone (PTH) level. So far, however, there is no prospective trial to
evaluate the effect of VDRAs administration on CVD prevention in hemodialysis patients.
Methods: The Japan Dialysis Active Vitamin D (J-DAVID) trial is a multi-center study with a prospective randomized
open-label blinded endpoint (PROBE) design. The subjects are maintenance hemodialysis patients whose serum
calcium is ≤10.0 mg/dL, phosphate is ≤6.0 mg/dL, and intact PTH is ≤180 pg/mL without taking any VDRA. The
subjects (target number is 972) are randomized to one of the two treatment arms: treatment with oral alfacalcidol
or treatment without using any VDRA and followed up for 48 months. The primary outcome is the composite of
fatal and nonfatal cardiovascular events (myocardial infarction, heart failure requiring hospitalization, stroke, aortic
dissection/rupture, amputation of lower limb due to ischemia, and cardiac sudden death, coronary revascularization,
and leg artery revascularization). The secondary outcome is all-cause death. The primary analysis will be the
intention-to-treat analysis of the primary endpoint.
Results: Between July 2008 and January 2011, a total of 976 participants were randomized. The final results are
expected in the second half of 2016.
Conclusions: The J-DAVID trial will provide valuable information whether or not administration of VDRA reduces
the risk of CVD in hemodialysis patients.
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Hemodialysis patients are at an extremely elevated risk of
death from all-cause and cardiovascular disease (CVD) in
Western countries [1, 2] and in Japan [3] as well. The ex-
cess risk may be attributable to impairment in traditional
[4] and nontraditional risk factors associated with chronic
kidney disease (CKD) [1] such as insulin resistance [5], in-
flammation [6], protein-energy wasting [7], and CKD-
mineral bone disorder (CKD-MBD) [8].
CKD-MBD is a systemic disorder in which abnormal-
ities in phosphate and calcium metabolism are causa-
tively involved not only in bone disease but also in
vascular calcification and poor clinical outcomes in pa-
tients with CKD [8]. Patients with reduced kidney func-
tion show phosphate retention, increased fibroblast
growth factor 23 (FGF23), impaired activation of 25-
hydroxyvitamin D (25(OH)D) to 1,25-dihydroxyvatiamin
D (1,25(OH)2D), and secondary hyperparathyroidism [9].
Observational cohort studies have revealed the inde-
pendent risk factors of mortality including elevated levels
of serum phosphate, calcium, and intact parathyroid hor-
mone (PTH) in hemodialysis patients in Western coun-
tries [10] and also in Japan [11, 12]. Furthermore, lower
serum levels of 25(OH)D [13] and 1,25(OH)2D [14] and
higher FGF23 [15] levels are reported to be predictive of
all-cause mortality in dialysis patients.
In addition to these abnormalities in laboratory tests,
the use of medications for CKD-MBD is known to be as-
sociated with clinical outcomes of patients with CKD.
The use of activated vitamin D sterols, or vitamin D re-
ceptor activators (VDRAs), was reported to be associ-
ated with lower risk of all-cause mortality [16–18],
CVD-related mortality [19, 20], and incident CVD [21]
in hemodialysis patients. Many, but not all [22], studies
reported such associations as previously reviewed [23].
The hazard ratios of VDRA use versus no use for all-
cause mortality were reported in the range between 0.55
and 0.75. In stratified analysis of a large cohort [16], the
lower risk of mortality in VDRA users was significant re-
gardless of serum levels of phosphate and calcium and
intact PTH levels.
Although these observational studies suggest the po-
tential benefit of VDRA, a controversy still exists on the
overall benefit of treatment with VDRA in dialysis pa-
tients. Activation of VDR may increase the risk of CVD
and mortality by increasing serum levels of calcium and
phosphate, which could promote vascular calcification.
Also, by increasing serum FGF23 production [24], a
novel factor potentially promoting left ventricular hyper-
trophy [25] and a predictor of congestive heart failure
(CHF) [26] and mortality [15], the use of VDRA may in-
crease the risk of myocardial remodeling and CHF. On
the contrary, VDRAs are shown to have potentially
beneficial non-mineral actions [23] such as suppressionof the renin-angiotensin system [27], modulation of im-
mune functions [28], anti-inflammatory effects [29], and
anti-atherosclerotic effects [30] on vascular cells. VDRA
inhibits cardiac hypertrophy in experimental animals
[31]. In addition, VDRA was reported to increase pro-
teins potentially protective against arterial calcification
[32, 33], including serum fetuin A [34] and klotho
expressed in arterial wall [35]. Based on these findings,
use of VDRA may suppress cardiac hypertrophy, athero-
sclerosis, arterial calcification, risk of CHF, atheroscler-
otic CVD, and mortality in patients with CKD. So far,
however, no randomized controlled trials (RCTs) have
been performed in hemodialysis patients to examine the
possible effects of VDRA on risk of CVD or mortality.
We designed an RCT, the Japan Dialysis Active Vitamin
D (J-DAVID) trial, to test a hypothesis that treatment with




The J-DAVID trial is an RCT with a prospective ran-
domized open-label blinded endpoint (PROBE) design.
Eligible patients were randomly allocated to one of the
two treatment arms: treatment with oral alfacalcidol
(1α-hydroxycholecalciferol) or treatment without any
VDRA. The follow-up period was 48 months (Fig. 1).
Population
The target population of this study was maintenance
hemodialysis patients whose serum calcium was ≤10.0 mg/
dL, phosphate was ≤6.0 mg/dL, and intact PTH was
≤180 pg/mL without taking any VDRA at screening.
These values derived from the 2006 version of the clinical
practice guideline by the Japanese Society for Dialysis
Therapy (JSDT) [36]. Eligibility criteria are shown in
Table 1.
Screening and enrollment
Eligible patients were screened at 207 study sites in 27
out of 47 prefectures in Japan (Fig. 2). The registration
forms were sent by FAX to the Data Center at Osaka
City University for registration and randomization. The
registration codes and the assigned treatment groups
were sent back by FAX to the attending physician within
two working days.
Randomization
Randomization was performed at a 1:1 ratio using a
computer-generated random sequence with a block
randomization method stratification by age (<65 years, ≥
65 years), sex, years on dialysis (<5 years, ≥5 years),
underlying renal disease (diabetic nephropathy, others),
and prior CVD (with, without). Region of dialysis centers
Intervention: treatment with oral alfacalcidol
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Fig. 1 Design of the J-DAVID study. IC informed consent, S screening, R randomization, M months, SAEs serious adverse events
Table 1 Eligibility criteria
Inclusion criteria
1. Signed informed consent
2. Patients on maintenance hemodialysis for 90 days or longer
3. Men or women aged ≥20 and ≤80 years old
4. No treatment with VDRAs for more than 4 weeks prior to this study
5. Serum calcium level ≤10.0 mg/dL
6. Serum phosphate level ≤6.0 mg/dL
7. Serum intact PTH level ≤180 pg/mL
Exclusion criteria
1. History within 12 weeks of myocardial infarction, stroke, aortic
dissection/rupture, amputation of a lower limb, coronary
revascularization or bypass surgery, lower limb revascularization or
bypass surgery
2. Heart failure of NYHA grade III or IV
3. Respiratory failure with PaO2 <60 mmHg or SpO2 <90 %
4. Life expectancy shorter than 1 year due to known malignant,
infectious, or other diseases
5. Abnormal liver function tests exceeding ×3 upper normal limits
6. Pregnant or lactating females or females planning to be pregnant
7. History of an allergic reaction to alfacalcidol
8. Participation to other interventional studies within 12 weeks prior
to this study
9. Inappropriate for this study as judged by an attending investigator
VDRAs vitamin D receptor activators, PTH parathyroid hormone, NYHA New
York Heart Association, PaO2 arterial oxygen pressure, SpO2 oxygen saturation
measured by pulse oxymeter
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sible regional disparities in life style, clinical practice pat-
terns, and risk of CVD.
Intervention and control treatment
The participants in the intervention arm were assigned to
treatment with oral alfacalcidol at a starting dosage of
0.5 μg per day, which derived from our previous cohort
study [19]. The participants in the control arm were
assigned to treatment without any VDRA. Except VDRAs,
all participants were eligible to receive any other medica-
tions for standard medical care including phosphate
binders and cinacalcet.
Follow-up
The clinical practice guidelines published by JSDT were
the guide for treatment of CKD-MBD in hemodialysis
patients. The 2006 version of the guideline [36] was ini-
tially used when the enrollment for J-DAVID was started
in 2008. After its revision in 2012 [37], the revised ver-
sion was used. Both versions of guideline recommended
the same target ranges for serum phosphate and cor-
rected calcium concentrations to be between 3.5 and
6.0 mg/dL and between 8.4 and 10.0 mg/dL, respect-
ively. Regarding intact PTH level, the 2006 version sug-
gested the target range between 60 and 180 pg/mL,
whereas the 2012 version suggested the range between




Fig. 2 Locations of the study sites. The colored areas indicate the 27
prefectures in which the 207 facilities were located
Table 2 Definition of CVD events as parts of the primary outcome
Acute myocardial infarction:
Clinical signs and symptoms such as chest pain or cardiogenic shock,
associated with abnormalities in biomarkers (creatine kinase, troponin,
etc.) and/or electric cardiogram (new abnormal Q-wave, ST elevation,
etc.) for myocardial infarction
Congestive heart failure:
Congestive heart failure (NYHA grade III or IV) requiring hospitalization,
excluding dyspnea due to non-cardiac causes (bronchial asthma, etc.)
Stroke:
Rapidly developing clinical signs of neurological deficit attributable to a
focal and/or total brain functions, without clear causes than vascular
origin, lasting for more than 24 h or leading to death (if not interrupted
by surgical operations or death). Stroke includes subarachnoidal
hemorrhage, intracranial hemorrhage, and cerebral infarction but
excludes transient ischemic attack, cerebrovascular disease due to
hematological disorders (leukemia, polycytemia vera, etc.), primary brain
tumors, and metastatic brain tumors. Stroke secondary to trauma is also
excluded
Aortic dissection/rupture:
Clinical symptom of chest pain and/or abdominal pain, and diagnosed
with imaging test such as contrast enhanced computed tomography
Amputation of ischemic limb:
Major amputations at ankle joint or proximal as treatment for patients
with symptom and/or signs of lower extremity ischemia
Cardiac sudden death:
Unexpected death from a cardiac cause that occurs within one hour
of symptom onset (witnessed) or within 24 h of last being observed
in normal health (unwitnessed)
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prior to PTH.
The participants in the intervention arm were asked to
avoid other VDRA preparations than oral alfacalcidol,
but they were allowed to receive one if clinically needed.
We defined the “drop-out” from the assigned treatment
at the time when alfacalcidol was not taken continuously
for more than 12 weeks in the intervention arm. The
participants in the control arm were asked to avoid alfa-
calcidol and any preparations of VDRA, but they were
allowed to receive one if clinically needed. The “drop-
out” from the assigned treatment was defined at the time
when treatment with any VDRA was done continuously
for more than 12 weeks in the control arm. Participants
who “dropped-out” from the assigned treatment were
followed up until the end of the planned period for the
intervention-to-treat (ITT) analysis.
Outcomes and outcome adjudication
The primary outcome was defined as the composite of
(1) fatal and nonfatal CVD events (acute myocardial in-
farction, congestive heart failure, stroke, aortic dissec-
tion/rupture, amputation of ischemic limb, and cardiac
sudden death), (2) coronary intervention (plain old bal-
loon angioplasty, stenting) or bypass grafting, (3) lower
limb artery intervention (plain old balloon angioplasty,
stenting) or bypass grafting. The definitions of the indi-
vidual CVD events are listed in Table 2. The secondary
outcome was defined as all-cause death. All these out-
comes are being prospectively adjudicated by the EventEvaluation Committee with the assigned treatment of
each case being masked to the Committee.Safety
All serious adverse events (SAEs) and laboratory data
are reported for safety. SAEs are defined as any undesir-
able experience during the study when the patient out-
come is (1) death, (2) life-threatening, (3) hospitalization
(initial or prolonged), (4) disability or permanent dam-
age, (5) congenital anomaly/birth defect, or (6) other im-
portant medical events. SAEs are being prospectively
adjudicated by the Event Evaluation Committee with the
assigned treatment of each case being masked to the
Committee. The laboratory data include serum intact
PTH, calcium, phosphate, alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, and others.Source data verification
We planned to perform source data verification (SDV) by
a sampling SDV. The minimum number of the extracted
patients (31) was determined by √N, where N = 976. Sam-
pling of participants was done by two steps using a
computer-generated sequence. First, dialysis facilities
were extracted, and then participants were sampled
from the participants in the facility. In this study,
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secondary outcomes.
Study organization
The Steering Committee, which was lead by three
academic investigators, nominated the members of the
Executive Committee which promoted this study by or-
ganizing the research group (J-DAVID Research Group)
comprised of dialysis facilities. Independent of the Steering
Committee, the Executive Committee, and the J-DAVID
Research Group, the J-DAVID study had the Data Center,
the Event Evaluation Committee, the Statistics Team, the
Independent Data Monitoring Committee, and the Audit
Team. These contributors to the J-DAVID study are col-
lectively called “J-DAVID Investigators” (Appendix).
Statistical considerations
Sample size and power calculation
Assuming (1) that 28 % of participants in the control
arm experience the primary outcome during the 4-year
period, (2) that the risk is reduced by 30 % in the inter-
vention arm, and (3) that 5 % of participants are lost to
follow-up, the trial requires a minimum of 972 partici-
pants to detect difference in proportion of the primary
endpoint between the two arms with 80 % power (ß level
of 0.2) and α level of 0.05.
We assumed the rate of the primary outcome based
on a cohort study of 45,390 prevalent Japanese
hemodialysis patients without history of prior myocar-
dial infarction or stroke at baseline [38]. The incidence
rates of myocardial infarction, cerebral infarction, and
cerebral bleeding during the 1-year follow-up (2004)
were 1.43, 2.53, and 0.21 per 100 patient-year, respect-
ively (4.17 in total) [38]. Some patients were expected to
have avoided such clinical events by timely interven-
tions. In addition, the incidence of these CVD events
and interventions are expected to be much higher in pa-
tients with prior CVD than those without prior CVD.
Thus, we assumed the rate of the primary outcome to
be 7–9 % annually.
We assumed 30 % of the relative risk reduction based
on previous observational cohort studies of prevalent
hemodialysis patients. The hazard ratio of oral VDRA
use versus nonuse for CVD mortality was reported to be
0.377 (95 % confidence interval 0.246–0.578) by a study
from Japan [11] and 0.59 (95 % confidence interval
0.40–0.88) by a study in Latin American countries [20].
Interim analysis
Interim analysis was planned to be performed once by
the Independent Data Monitoring Committee upon re-
quest by the Committee with a Haybittel-Peto method.
On the interim analysis, 0.0001 of α is to be spent, andthe final α is to be reduced to 0.0499 to maintain the
study-wise α level of 0.05.
Analysis plan
We defined three populations for analysis: full analysis set
(FAS), per-protocol set (PPS), and modified per-protocol
set (modified PPS). (1) The FAS consists of all participants
who were randomized and participants who “dropped-out”
from the assigned treatment are not censored at the time
of “drop-out.” (2) The PPS consists of all participants who
were randomized, but participants are censored at the time
of “drop-out” from the assigned treatment. (3) The modi-
fied PPS consists of all participants who were randomized,
and participants are censored as follows: In the control
arm, participants are censored at the time of “drop-out”
from the assigned treatment. In the intervention arm,
participants who are censored at the time of “drop-out”
from the assigned treatment with oral alfacalcidol, if
no VDRA is given in place of alfacalcidol. Participants
in the intervention arm are not censored at the time of
“drop-out” from the assigned treatment with oral
alfacalcidol, if the participants are kept treated with an
oral or intravenous VDRA other than alfacalcidol, but
such patients are censored at the time when any VDRA is
not given continuously for more than 12 weeks.
The primary analysis will be performed using time
after randomization to the occurrence of the primary
composite outcome with the FAS based on the Kaplan-
Meier method with log-rank test. Hazard ratio and con-
fidence interval will be calculated with an unadjusted
Cox proportional hazards model for the primary com-
posite outcome and its breakdown. The key secondary
analysis will be done with time after randomization to
the secondary outcome (all-cause death) with the FAS
based on the same methods as above. Additionally, the
primary and secondary outcomes will be analyzed with
the PPS and the modified PPS as sensitivity analysis.
Results
Participant recruitment and baseline characteristics
Recruitment of participants began in July 2008 and com-
pleted in January 2011. Eligibility was assessed in 1289
patients, and 976 patients from 108 dialysis facilities
were enrolled and randomized. Table 3 gives the baseline
characteristics of the total participants.
Discussion
The J-DAVID study was originally designed to test a hy-
pothesis that treatment with VDRA reduces the risk of
CVD events as the primary endpoint and/or all-cause
mortality as the secondary endpoint in hemodialysis pa-
tients. This hypothesis was based on the observational
clinical studies and experimental studies reporting po-
tential benefit of VDRAs.
Table 3 Baseline characteristics of the participants
Total number 976
Age (years) 63.5 ± 10.0
Sex, men (%) 60.5
Underlying renal disease, diabetic nephropathy (%) 42.5
Years on hemodialysis, 5 years or longer (%) 52.2
Prior cardiovascular disease, present (%) 25.1
Serum calcium (mg/dL) 8.82 ± 0.60
Serum phosphate (mg/dL) 4.56 ± 0.91
Serum intact parathyroid hormone (pg/mL) 86.6 (46.8–130.0)
Use of calcium carbonate (%) 82.9
Use of sevelamer hydrochloride (%) 32.0
Use of lanthanum carbonate (%) 12.4
Use of cinacalcet hydrochloride (%) 5.9
The table gives number, percentage, mean ± standard deviation, or median
(25th–75th percentile)
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2008, there have been two published RCTs regarding the
use of VDRA and CVD in patients with CKD. The first
one was the PRIMO study [39] and the second one was
the OPERA study [40], both of which examined the ef-
fects of oral paricalcitol on left ventricular hypertrophy
as determined by cardiac magnetic resonance imaging
among predialysis patients with CKD. These two studies
showed no significant effect of treatment with paricalci-
tol on the primary endpoint. Of note, however, CVD
events were fewer in the paricalcitol group than the pla-
cebo group in the PRIMO study, and the number of
hospitalization was fewer in the paricalcitol group
than the placebo group in the OPERA study. These
results are an additional support for the hypothesis of
the J-DAVID study. So far, no RCT has been published
that examined the VDRA’s effect on CVD events or mor-
tality in hemodialysis patients as well as in predialysis pa-
tients with CKD.
The use or nonuse of VDRA affects serum levels of
phosphate, calcium, and intact PTH. Therefore, in order
to maintain the key laboratory data within the target
ranges, dietary therapy, and other medications would be
changed over time after starting the assigned treatment.
As compared with the participants in the control arm,
the participants in the intervention arm may have higher
levels of serum calcium and phosphate, and lower levels
of intact PTH level on average, after starting the
assigned treatment. More patients in the intervention
arm may be treated with non-calcium-containing phos-
phate binders, whereas more patients in the control arm
may be treated with cinacalcet. A meta-analysis showed
a lower risk of death was associated with the use of non-
calcium containing phosphate binders as compared with
calcium containing phosphate binders in patients withCKD [41]. The same observation was made for either
sevelamer hydrochloride [42] or lanthanum carbonate
[43] in the elderly hemodialysis patients. Also, there is a
discussion whether or not cinacalcet has cardio-protective
actions [44]. Therefore, any effects on the primary and
secondary endpoints in the J-DAVID study will not be
purely attributable to the effect of alfacalcidol. Rather, this
study would clarify whether the VDRA-based treatment is
better than the treatment avoiding VDRA in terms of
CVD prevention when other medications are available.
The current clinical practice guidelines for the manage-
ment of CKD-MBD are largely based on observational co-
hort studies showing the associations of laboratory tests
with all-cause mortality. However, the medications used
for the control of the laboratory tests may be more im-
portant for clinical outcomes than the achieved serum
levels of phosphate, calcium, and PTH. According to a re-
cent meta-analysis [45], there are only weak and imprecise
correlations of drug effects on serum levels of phosphate,
calcium, and PTH with all-cause and cardiovascular death
in patients with CKD, suggesting that the drug’s non-
mineral actions favorably affected these clinical endpoints.
The same has been suggested also by previous cohort
studies in which the use of VDRAs [16–21] or the use of
phosphate-binders [21, 46] were associated with a lower
risk of all-cause death, CVD death, or incident CVD in
dialysis patients, even after adjusted for serum calcium,
phosphate, and PTH levels. The J-DAVID study will reveal
whether or not the VDRA treatment reduces CVD and/or
mortality even when the current target ranges of phos-
phate, calcium, and intact PTH are respected.Conclusions
The J-DAVID study will be the first trial providing valu-
able information whether or not oral VDRA-based treat-
ment reduces the risk of CVD and/or mortality in
hemodialysis patients who are treated by respecting the
recommended target ranges of serum phosphate, cal-
cium, and intact PTH.Ethical approval and consent to participate
This study was performed in accordance with the Declar-
ation of Helsinki and the Ethical Guidelines for Clinical
Research by the Ministry of Health, Labor and Welfare,
Japan (July 30, 2003; December 28, 2004 all amendments;
July 31, 2008 all amendments). The protocol of this study
was first reviewed and approved by the Ethics Committee
of Osaka City University Graduate School of Medicine,
Osaka, Japan (No. 1227, 1297, 1385, and 1525), and by the
Institutional Review Board/Ethics Committee at each
study site. The study plan had been registered at the Uni-
versity Hospital Medical Information Network Clinical
Trials Registry (UMIN-CTR) before the first participant
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All participants gave informed consent before enrollment.
Consent for publication
Not applicable.
Availability of data and materials
No data is publicly available at present because data col-
lection is still ongoing at the time of submission.
Appendix
Study organization “J-DAVID Investigators”
The following list indicates the contributors’ names with
institutions and prefectures in parenthesis:
Steering Committee
Tetsuo Shoji* (Osaka City University, Osaka), Masaaki
Inaba (Osaka City University, Osaka), and Yoshiki
Nishizawa (Osaka City University, Osaka)
*Principal investigator
Executive Committee
Tadao Akizawa (Showa University School of Medicine,
Tokyo), Ryoichi Ando (Japanese Red Cross Musashino
Hospital, Tokyo), Rieko Eriguchi (Fukuoka Renal Clinic,
Fukuoka), Akira Fujimori (Konan Hospital, Hyogo),
Masafumi Fukagawa (Tokai University, Kanagawa),
Tetsuya Hashimoto (Tojinkai Hospital, Kyoto), Hideki
Hirakata (Japanese Red Cross Fukuoka Hospital, Fukuoka),
Hirokazu Honda (Showa University, Tokyo), Tatsuo
Hosoya (Jikeikai University School of Medicine, Tokyo),
Daijo Inaguma (Japanese Red Cross Nagoya Daini Hos-
pital, Aichi), Toru Inoue (Higasikouri Hospital, Osaka),
Yoshitaka Isaka (Osaka University Graduate School of
Medicine, Osaka), Kunitoshi Iseki (University Hospital of
the Ryukyus, Okinawa), Mari Ishida (Tokai University
Hachioji Hospital, Tokyo), Eiji Ishimura (Osaka City Uni-
versity, Osaka), Noritomo Itami (Nikko Kinen Hospital,
Hokkaido), Chiharu Ito (Haga Red Cross Hospital,
Tochigi), Minoru Ito (Yabuki Clinic, Yamagata), Noriyuki
Iwamoto (Tojinkai Hospital, Kyoto), Ryusuke Kakiya
(Meijibashi Hospital, Osaka), Toshitaka Kakuta (Tokai
University Hachioji Hospital, Tokyo), Toru Kawai (Chuou
Naika Clinic, Hiroshima), Hideki Kawanishi (Tsuchiya
General Hospital, Hiroshima), Shuzo Kobayashi (Shonan
Kamakura General Hospital, Kanagawa), Kazutaka Kukita
(Sapporo Hokuyu Hospital, Hokkaido), Junko Kumagai
(Omachi Tsuchiya Clinic, Hiroshima), Eiji Kusano (JCHO
Utsunomiya Hospital, Tochigi), Kiyoshi Maekawa (Fujiidera
Shirasagi Clinic, Osaka), Ikuto Masakane (Yabuki
Hospital, Yamagata), Hiroya Masaki (Kansai Medical Uni-
versity Hakii Hospital, Osaka), Mikio Okamura (Ohno
Memorial Hospital, Osaka), Jun Minakuchi (Kawashima
Hospital, Tokushima), Koji Mitsuiki (Japanese Red CrossFukuoka Hospital, Fukuoka), Takashi Mizukuchi (Kochi
Takasu Hospital, Kochi), Satoshi Morimoto (Tokyo
Women’s Medical University, Tokyo), Yoshihiro Motomiya
(Suiyukai Clinic, Nara), Takeshi Nakanishi (Hyogo College
of Medicine, Hyogo), Tatsuya Nakatani (Osaka City Univer-
sity, Osaka), Tomohiko Naruse (Kasugai Municipal Hos-
pital, Aichi), Shigeo Negi (Wakayama Medical University,
Wakayama), Mitsushige Nishikawa (Kansai Medical Uni-
versity Internal Medicine II, Osaka), Kosaku Nitta (Tokyo
Women’s Medical University, Tokyo), Tetsuya Ogawa
(Tokyo Women’s Medical University Medical Center East,
Tokyo), Seiji Ohira (Sapporo Kita Clinic, Hokkaido),
Takayasu Ohtake (Shonan Kamakura General Hospital,
Kanagawa), Senji Okuno (Shirasagi Hospital, Osaka),
Toshihiko Ono (Tojinkai Hospital, Kyoto), Kazumichi Ota
(Kochi Takasu Hospital, Kochi), Shigeru Otsubo (Sangenjaya
Hospital, Tokyo), Toshinobu Sato (JCHO Sendai Hospital,
Miyagi), Yuzuru Sato (Sato Junkankika Naika, Ehime),
Takashi Shigematsu (Wakayama Medical University,
Wakayama), Toshitsugu Sugimoto (Shimane University
Faculty of Medicine, Shimane), Masashi Suzuki (Shinrakuen
Hospital, Niigata), Tsutomu Tabata (Inoue Hospital,
Osaka), Yoshio Taguma (JCHO Sendai Hospital, Miyagi),
Hideki Tahara (Osaka City University, Osaka), Yoshiaki
Takemoto (Osaka City University, Osaka), Kenji Tanaka
(Suiyukai Clinic, Nara), Masaru Tanaka (Tanaka Kitanoda
Hosipital, Osaka), Hideki Tanida (Yabuki Hospital,
Yamagata), Masatomo Taniguchi (Kyushu University,
Fukuoka), Yoshihiro Tominaga (Japanese Red Cross
Nagoya Daini Hospital, Aichi), Yoshiharu Tsubakihara
(Graduate School of Health Care Sciences, Jikei Insutitute,
Osaka), Yoshihiro Tsujimoto (Inoue Hospital, Osaka),
Kazuhiko Tsuruya (Graduate School of Medical Sciences,
Kyushu University, Fukuoka), Yuzo Watanabe (Kasugai
Municipal Hospital, Aichi), Kunihiro Yamagata (Faculty of
Medicine, University of Tsukuba, Ibaraki), Tomoyuki
Yamakawa (Shirasagi Hospital, Osaka), Shozo Yano
(Shimane University, Shimane), Keigyou Yoh (University of
Tsukuba, Ibaraki), Keitaro Yokoyama (Jikeikai University
School of Medicine, Tokyo), Noriaki Yorioka (Hiroshima
Kidney Organization, Hiroshima), Mitsuru Yoshimoto
(Ohno Memorial Hospital, Osaka), Kenji Yuasa (Kochi
Takasu Hospital, Kochi)
J-DAVID Research Group
The following list indicates J-DAVID study sites by
prefecture from which one or more participants were
enrolled, excluding the institutions of the Executive
Committee members:
Aichi prefecture—Kazuhiro Fujisawa (Kasugai Central
Clinic), Sumie Tawada (Kojukai Kasugai Hospital),
Satoshi Yamaguchi (Seto Kyoritsu Clinic)
Chiba prefecture—Yasuho Kimura (Shin Kashiwa
Clinic)
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Hospital)
Fukuoka prefecture—Itsuko Ishida (Harasanshin Hos-
pital Gofukumachi Jin Clinic), Tetsuo Komota (Komota
Clinic), Dai Matsuo (Hirao Clinic), Hiroaki Takamura
(Hara Hospital)
Gunma prefecture—Kyoko Ito (Heisei Hidaka Clinic)
Hokkaid prefecture—Nobuo Hashimoto (H·N·Medic),
Hironori Ishida (Kitasaito Hospital), Yoshitomo Itami
(Higashi Muroran Satellite Clinic), Hirofumi Kon (KKR
Sapporo Medical Center), Fumiaki Kumagai (Tomakomai
Nissho Hospital)
Hyogo prefecture—Takuma Mabuchi (Tanaka Wadayama
Clinic), Furuta Minoru (Aoi Hospital), Shiro Okajima
(Tanaka Iin), Noriko Tanaka (Hojo Tanaka Hospital)
Ibaraki prefecture—Takashi Ishizu (Tsukuba Central
Hospital), Takashi Ishizu (Central Jin Clinic Ryugasaki),
Hiroshi Kikuchi (Kikuchi Medical Clinic), Masakazu
Otsuka (Tokiwa Clinic), Atsushi Ueda (Namegata Dis-
trict General Hospital)
Kanagawa prefecture—Naoto Ishida (Seichi Clinic),
Mikako Nagaoka (Honatsugi Medical Clinic), Ayaka
Tanaka (Bousei Oone Clinic)
Kochi prefecture—Yasukazu Sen (Kochi Takasu Hospital
Aki Clinic)
Kyoto prefecture—Naoto Adachi (Mabuchi Clinic),
Masaki Koyama (Nishijin Hospital)
Miyagi prefecture—Kosei Kurosawa (Izumi Kurosawa
Clinic), Akira Yuza (Dainohara Internal Medicine Clinic)
Oita prefecture—Kazuhiro Matsuyama (Matsuyama Iin
Oita Nephrology Clinic), Makoto Matsuyama (Oita
Nakamura Hospital)
Okayama prefecture—Masaki Fukushima (Shigei Med-
ical Research Hospital)
Okinawa prefecture—Akira Higa (Shuri Jokamachi
Clinic Daini), Kentaro Kohagura (University Hospital of
the Ryukyus)
Osaka prefecture—Kaori Adachi (Kitatatsumi Shirasagi
Clinic – Shirasagi Minami Clinic), Kiyoshi Goto (Ono
Naika), Yuka Hosomi (Inoue Hospital), Noriko Kambara
(Kanbara Hospital), Hironori Kawamura (Kawamura
Clinic), Eiji Kimoto (Meijibashi Hospital), Satoshi Mikami
(Higashikouri Hospital), Michiko Miura (Nagai Clinic),
Harumi Nagayama (Nagayama Clinic), Koji Nakanishi
(Nakanishi Clinic), Sei Nakatani (Ikuno Aiwa Hospital),
Yasue Obi (Obi Clinic), Shigeki Okada (Okada Clinic),
Mikio Okamura (Ohno Memorial Hospital), Nobuaki
Okuda (Okuda Clinic), Senji Okuno (Shirasagi Clinic),
Mayumi Sakurai (Jurakukai Clinic), Hidekazu Shimizu
(Onoyama Clinic), Shigeichi Shoji (Shirasagi Hosipital),
Kenzo Suzuki (Kadoma Clinic Aiwa Clinic), Akiko Tanaka
(Tanaka Habikino Clinic), Keiko Tanaka (Kitahanada
Clinic), Hitoshi Tanishita (Hanwa Memorial Hospital),
Takeshi Wakikawa (Sakai Onshinkai Hospital), IbukiYajima (Ibuki Clinic), Yoshiaki Yamada (Arisawa General
Hospital), Yasuo Yamakoshi (Ishikiriseiki Hospital), Shozo
Yodoi (Yodoi Hospital)
Shimane prefecture—Yasutoshi Himeno (Himeno Clinic),
Kazushi Shigeno (Ohda Himeno Clinic), Keiko Suzuki
(Ohtsuka Clinic)
Tochigi prefecture—Ryuta Sato (Haga Red Cross Hospital)
Tokushima prefecture—Kazuhiko Kawahara (Kamojima
Kawashima Hospital)
Tokyo prefecture—Hirokazu Honda (Ebara Clinic),
Noritsugu Imamura (Minami-Tamachi Clinic), Naohiko
Kato (Shinagawa Jin Clinic), Taku Morito (Towa Hos-
pital), Seizo Murai (Iidabashi-Murai Iin), Shiori Osada
(Tokyo Ayase Kidney Center), Jun Shiota (Kichijoji
Asahi Hospital), Shinya Suganuma (Kidney Clinic
Setagaya), Daijiro Uetake (Toyosu Kidney Dialysis
Clinic), Ryo Yamamoto (Tateishi Jin Clinic)
Wakayama prefecture—Akio Kaketaka (Kihoku Clinic),
Toshihiro Kodama (Kinokawa Clinic), Naoya Kodama
(Kisen KD Clinic), Kunio Koshimura (Kumanoji Clinic),
Akefumi Maeda (Kodama Hospital), Sadako Tamai
(Taniguchi Hospital), Takuji Ujita (Ujita Circulation
Disease Clinic)
Yamagata prefecture—Minoru Ito (Yabuki Hospital),
Hideki Tanida (Tendo Onsen Yabuki Clinic)Data Center
Yoshinobu Hirayama1) (Osaka City University, Osaka),
Taisuke Hojo2) (Osaka City University, Osaka), Toshiyoshi
Tominaga3) (Osaka City University, Osaka), Yuichi Kato4)
(Osaka City University, Osaka), Hisako Fujii5) (Osaka City
University, Osaka)
1) 2008–2010, 2) 2010–2012, 3) 2012–2014, 4) 2014–
2016, 5) 2008–2016Statistical Team
Mitsuru Fukui* (Osaka City University, Osaka)
*ChiefEvent Evaluation Committee
Hiroki Hase* (Toho University Ohashi Medical Center,
Tokyo), Minoru Yoshiyama (Osaka City University,
Osaka), Yuji Ikari (Tokai University School of Medicine,
Kanagawa)
*ChiefIndependent Data Monitoring Committee
Shinichiro Ueda* (University of the Rryukus, Okinawa),
Toyoaki Murohara (Nagoya University, Aichi), Shinichi
Nishi (Kobe University, Hyogo)
*Chief
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